Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

Stocktradesmoon Nov. 8 at 5:20 AM

$ABCL On November 5, 2025 - State Of Michigan Retirement System filed a 13F-HR form disclosing ownership of 400,000 shares of AbCellera Biologics Inc. valued at $2,012,000 USD as of September 30, 2025. $ABCL The entity filed a previous 13F-HR on August 5, 2025 disclosing 49,225 shares of AbCellera Biologics Inc.. This represents a change in shares of 712.60% during the quarter.

0 · Reply

Stocktradesmoon Nov. 8 at 3:10 AM

$ABCL $ABCL this morning fell to $3.42 and now at $4.20 during after hour trading. Just a 20% recovery from the morning low. No big deal.

0 · Reply

Stocktradesmoon Nov. 8 at 3:09 AM

$ABCL

0 · Reply

estatebuyersmia Nov. 8 at 2:58 AM

$ABCL some people trade stocks, others marry them...

1 · Reply

Odoji Nov. 8 at 2:58 AM

$ABCL

0 · Reply

estatebuyersmia Nov. 8 at 2:57 AM

$ABCL that after hours spike means nothing...

0 · Reply

estatebuyersmia Nov. 8 at 2:56 AM

$ABCL Its going lower.. Ill just wait...

0 · Reply

Stocktradesmoon Nov. 8 at 2:33 AM

$ABCL 👀🤫😉

0 · Reply

Stocktradesmoon Nov. 8 at 2:32 AM

$ABCL $ABCL 🤔🤫 I was wrong until I was right… This dip was devoured today as expected.

0 · Reply

Stocktradesmoon Nov. 8 at 1:27 AM

$ABCL You Greedy pig 🐽 should have bought at $3.42 👀😉

0 · Reply

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 1 day ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 4 weeks ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 4 weeks ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 5 weeks ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 2 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 2 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 3 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 5 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 6 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 6 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 6 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 6 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 8 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 9 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 10 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 10 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 11 months ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 8, 2024, 12:05 PM EDT - 1 year ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 19, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 1 year ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 1 year ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Stocktradesmoon Nov. 8 at 5:20 AM

0 · Reply

Stocktradesmoon Nov. 8 at 3:10 AM

$ABCL $ABCL this morning fell to $3.42 and now at $4.20 during after hour trading. Just a 20% recovery from the morning low. No big deal.

0 · Reply

Stocktradesmoon Nov. 8 at 3:09 AM

$ABCL

0 · Reply

estatebuyersmia Nov. 8 at 2:58 AM

$ABCL some people trade stocks, others marry them...

1 · Reply

Odoji Nov. 8 at 2:58 AM

$ABCL

0 · Reply

estatebuyersmia Nov. 8 at 2:57 AM

$ABCL that after hours spike means nothing...

0 · Reply

estatebuyersmia Nov. 8 at 2:56 AM

$ABCL Its going lower.. Ill just wait...

0 · Reply

Stocktradesmoon Nov. 8 at 2:33 AM

$ABCL 👀🤫😉

0 · Reply

Stocktradesmoon Nov. 8 at 2:32 AM

$ABCL $ABCL 🤔🤫 I was wrong until I was right… This dip was devoured today as expected.

0 · Reply

Stocktradesmoon Nov. 8 at 1:27 AM

$ABCL You Greedy pig 🐽 should have bought at $3.42 👀😉

0 · Reply

Fast_Eddie_Felson Nov. 8 at 1:22 AM

$ABCL are there just two retards left posting here? 😮

0 · Reply

Chebsmcgee Nov. 8 at 12:59 AM

$ABCL lmao

0 · Reply

estatebuyersmia Nov. 8 at 12:55 AM

$ABCL READ....

0 · Reply

Stocktradesmoon Nov. 7 at 11:58 PM

$ABCL

0 · Reply

Stocktradesmoon Nov. 7 at 10:53 PM

$ABCL

0 · Reply

estatebuyersmia Nov. 7 at 10:43 PM

$ABCL Investors with real cognitive brains will understand what Iam saying.... I dont have to defend my position.. The market is dictating the true valuation...

1 · Reply

estatebuyersmia Nov. 7 at 10:39 PM

$ABCL YOU WOULD HAVE TO BE AN IDIOT TO SHORT A 3 DOLLAR STOCK WITH 650 MILLION IN CASH.. BAD BET

0 · Reply

estatebuyersmia Nov. 7 at 10:35 PM

$ABCL Iam not short this stock but if you choose to bury your head in the sand so be it. Ill buy $ABCL if it dips to 3.20.

0 · Reply

estatebuyersmia Nov. 7 at 10:33 PM

$ABCL All you bulls have to realize that PROFITABILTY DRIVES STOCK PRICES HIGHER, NOT HOPE, NOT PRAYERS, NOT SENTIMENT... EVENTUALLY $ABCL will be there but its years off.... YEARS.. In the mean time it will trade up and down until they get a new milestone payment or a drug trial shows postivity. Thats the truth....

0 · Reply

Stocktradesmoon Nov. 7 at 10:30 PM

$ABCL Our new short on this board

0 · Reply

estatebuyersmia Nov. 7 at 10:28 PM

$ABCL The sell off isnt OVER...

0 · Reply

Amires Nov. 7 at 10:05 PM

$ABCL What does this have to do with ABCL?

2 · Reply

Market Cap	1.35B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	13,522,200
Avg Vol	5,339,824
Day's Range	N/A - N/A
Shares Out	298.83M
Stochastic %K	21%
Beta	0.70
Analysts	Strong Sell
Price Target	$9.29